Cytokinetics (CYTK) Misses Q3 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Cytokinetics Reports Third Quarter 2024 Financial Results
November 6, 2024 4:00 PM ESTRolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3
COMET-HF, Confirmatory Phase 3 Clinical Trial of Omecamtiv Mecarbil,
and AMBER-HFpEF, Phase 2 Clinical Trial of CK-586, Expected to Begin in Q4
Plan to Advance CK-089, Fast Skeletal Muscle Troponin Activator,
into First-In-Human Study in Q4 2024
~$1.3 Billion in Cash, Cash Equivalents and Investments as of September 30, 2024
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a... More
